Results 151 to 160 of about 2,131 (185)

Fremanezumab for the prevention of chronic and episodic migraine

Drugs of Today, 2019
On September 15, 2018, the U.S. Food and Drug Administration (FDA) approved subcutaneous fremanezumab, a calcitonin gene-related peptide (CGRP) monoclonal antibody, for the treatment of episodic and chronic migraine in adults, with two recommended dosages: 225 mg monthly or 675 mg every 3 months.
L, Lionetto, F, Cipolla, M, Guglielmetti, P, Martelletti   +3 more
openaire   +2 more sources

Fremanezumab

Reactions Weekly, 2023
openaire   +2 more sources

Fremanezumab in Children and Adolescents with Episodic Migraine

New England Journal of Medicine
Fremanezumab, a humanized monoclonal antibody that selectively targets calcitonin gene-related peptide, is approved for the prevention of migraine in adults. Evidence from randomized, controlled trials in children and adolescents is needed.We randomly assigned participants 6 to 17 years of age with a diagnosis of episodic migraine (defined as migraine ...
Andrew D, Hershey, Christina L, Szperka, Piero, Barbanti, Patricia, Pozo-Rosich, Petra, Bittigau, Steve, Barash, Juline, Bryson, Yoel, Kessler, Yael, Carmeli Schwartz, Verena, Ramirez Campos, Xiaoping, Ning   +10 more
openaire   +2 more sources

Fremanezumab: Pediatric First Approval

Pediatric Drugs
Fremanezumab (fremanezumab-vfrm; AJOVY®) is a humanized monoclonal antibody developed by Teva Pharmaceuticals to selectively target calcitonin gene-related peptide (a vasodilatory neuropeptide involved in the pathophysiology of migraine). Fremanezumab was first approved in September 2018 in the USA for the prevention of migraine in adults.
openaire   +2 more sources

Fremanezumab-associated injection site alopecia

BMJ Case Reports
Calcitonin gene-related peptide (CGRP) inhibitors, in the form of injectable monoclonal antibodies, are a newer class of drugs for the prevention of migraine headaches. In clinical trials, they have been found to be effective with good tolerance and few adverse effects. Alopecia has been increasingly noted as a post-marketing event associated with CGRP
Mark, Esguerra, Emily Rubenstein, Engel
openaire   +2 more sources

Fremanezumab as a preventive treatment for episodic and chronic migraine

Expert Review of Neurotherapeutics, 2019
Introduction: The importance of calcitonin gene-related peptide (CGRP) in migraine pathogenesis is well established. Fremanezumab is a humanized IgG2a monoclonal antibody that binds to CGRP. Areas covered: In this paper, we review the development of fremanezumab, from early development into approval.
Marcelo E, Bigal, Sarah, Walter, Alan M, Rapoport   +2 more
openaire   +2 more sources

Fremanezumab

Reactions Weekly, 2022
openaire   +1 more source

Erenumab/fremanezumab/galcanezumab

Reactions Weekly, 2021
openaire   +2 more sources

Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study

Headache, 2021
Dana Franznick, Richard B. Lipton, Michael J Seminerio   +2 more
exaly  

Hypersensitivity to galcanezumab with tolerance to erenumab and fremanezumab

The Journal of Allergy and Clinical Immunology: In Practice, 2023
Beatriz, González-Cano, Victoria, Villalobos-Violán, Mar, Gandolfo-Cano, Maria Jesús, Trujillo-Trujillo, Ester, Mohedano-Vicente, Eloína, González-Mancebo   +5 more
openaire   +2 more sources